Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03133676 · ClinicalTrials.gov registry record · Phase 1
A Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of KA34 in Subjects With Knee Osteoarthritis
A Phase 1 study, sponsored by Calibr, a division of Scripps Research.
- Completed
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
NCT03133676 is a Phase 1 study that has completed, run by Calibr, a division of Scripps Research. The registered enrollment target is 60 participants.
The verdict
NCT03133676, a Phase 1 study, has completed, sponsored by Calibr, a division of Scripps Research.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
Study Summary
This study will evaluate the safety and tolerability of KA34 when administered via intra-articular injection to subjects with osteoarthritis of the knee.
Interventions
- DRUG Placebo
- DRUG KA34
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2018-05-02 |
| Est. Completion | 2020-04-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03133676
The ClinicalTrials.gov registry entry for NCT03133676 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Calibr, a division of Scripps Research, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03133676 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03133676 about?
NCT03133676 is a clinical study titled "A Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of KA34 in Subjects With Knee Osteoarthritis". This study will evaluate the safety and tolerability of KA34 when administered via intra-articular injection to subjects with osteoarthritis of the knee.
What is the current status of trial NCT03133676?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2018-05-02. Estimated completion is 2020-04-28.
What interventions are being tested in trial NCT03133676?
The interventions under investigation include: Placebo (DRUG), KA34 (DRUG).
Who is sponsoring clinical trial NCT03133676?
This trial is sponsored by Calibr, a division of Scripps Research, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.